Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tom Cupedo

Showing results (71-80 of 77) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 77 results.
Blood|December 18, 2025
Circulating tumor cells in myeloma are a compound biomarker for bone marrow high-risk genomic alterations and tumor loadCathelijne Fokkema, Luca Bertamini, Madelon M E de Jong, et al.
Blood|February 26, 2025
Aberrant single-cell phenotype and clinical implications of genotypically defined polyclonal plasma cells in myelomaMatteo Claudio Da Viá, Francesca Lazzaroni, Antonio Matera, et al.
Blood|October 8, 2025
Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasoneLuca Bertamini, Cathelijne Fokkema, Paula Rodriguez-Otero, et al.
Nature Communications|July 24, 2020
B cell zone reticular cell microenvironments shape CXCL13 gradient formationJason Cosgrove, Mario Novkovic, Stefan Albrecht, et al.
Nature|December 10, 2015
Interleukin-22 promotes intestinal-stem-cell-mediated epithelial regenerationCaroline A Lindemans, Marco Calafiore, Anna M Mertelsmann, et al.
Hemasphere|October 15, 2025
European Myeloma Network Group Consensus Statement on the use of next-generation sequencing for prognostic stratification of newly diagnosed multiple myelomaNiccolò Bolli, Mattia D'Agostino, Tina Bagratuni, et al.
Blood|February 28, 2025
The bone marrow NK cell profile predicts MRD negativity in patients with multiple myeloma treated with daratumumab-based therapyCharlotte L B M Korst, Sabrin Tahri, Carolien Duetz, et al.
Pageof 8

Showing results (71-80 of 77) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 77 results.
Blood|December 18, 2025
Circulating tumor cells in myeloma are a compound biomarker for bone marrow high-risk genomic alterations and tumor loadCathelijne Fokkema, Luca Bertamini, Madelon M E de Jong, et al.
Blood|February 26, 2025
Aberrant single-cell phenotype and clinical implications of genotypically defined polyclonal plasma cells in myelomaMatteo Claudio Da Viá, Francesca Lazzaroni, Antonio Matera, et al.
Blood|October 8, 2025
Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasoneLuca Bertamini, Cathelijne Fokkema, Paula Rodriguez-Otero, et al.
Nature Communications|July 24, 2020
B cell zone reticular cell microenvironments shape CXCL13 gradient formationJason Cosgrove, Mario Novkovic, Stefan Albrecht, et al.
Nature|December 10, 2015
Interleukin-22 promotes intestinal-stem-cell-mediated epithelial regenerationCaroline A Lindemans, Marco Calafiore, Anna M Mertelsmann, et al.
Hemasphere|October 15, 2025
European Myeloma Network Group Consensus Statement on the use of next-generation sequencing for prognostic stratification of newly diagnosed multiple myelomaNiccolò Bolli, Mattia D'Agostino, Tina Bagratuni, et al.
Blood|February 28, 2025
The bone marrow NK cell profile predicts MRD negativity in patients with multiple myeloma treated with daratumumab-based therapyCharlotte L B M Korst, Sabrin Tahri, Carolien Duetz, et al.
Pageof 8